Amanda L Missel1, Laura R Saslow2, Dina H Griauzde3,4, Donna Marvicsin2, Ananda Sen5,6, Caroline R Richardson5, Xuefeng Liu7. 1. Department of Learning Health Sciences, Medical School, University of Michigan, 1160 NIB 300, Ann Arbor, MI, 48104, USA. missaman@umich.edu. 2. Department of Health Behavior and Biological Sciences, School of Nursing, University of Michigan, Ann Arbor, MI, USA. 3. Internal Medicine, Medical School, University of Michigan, Ann Arbor, MI, USA. 4. VA Ann Arbor Healthcare System, Ann Arbor, MI, USA. 5. Family Medicine, Medical School, University of Michigan, Ann Arbor, MI, USA. 6. Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA. 7. Systems, Populations and Leadership, University of Michigan, Ann Arbor, MI, USA.
Abstract
INTRODUCTION: Chronic inflammation is associated with the development, progression and long-term complications of type 2 diabetes. Hyperglycemia is associated with chronic low-grade inflammation, and thus has become the focus of many screening and treatment recommendations. We hypothesize that insulin may also be associated with inflammation and may be an additional factor to consider in screening and treatment. METHODS: This study used National Health and Nutrition Examination Survey data from 2005 to 2010 to analyze the association between fasting insulin and C-reactive protein (CRP). A two-part model was used due to the high number of values reported as 0.1 mg/L. Two models were analyzed, both with and without the addition of waist circumference to other covariates in the model. RESULTS: The final sample included 4527 adults with a mean age of 43.31 years. In the first model, higher fasting insulin was associated with increased odds of CRP > 0.1 mg/L (OR = 1.02, p < .001) and with higher CRP (β = 0.03, p < .001). In the adjusted model, including waist circumference as a covariate, higher fasting insulin was not associated with CRP > 0.1 mg/L (OR = 1.00, p = .307) but the association between higher fasting insulin and higher continuous CRP remained significant (β = 0.01, p = .012). CONCLUSION: This study found that higher fasting insulin is associated with higher CRP. These results suggest that treatment approaches that simultaneously decrease insulin levels as well as glucose levels may provide additive anti-inflammatory effects, and therefore may improve long-term outcomes for adults with type 2 diabetes.
INTRODUCTION: Chronic inflammation is associated with the development, progression and long-term complications of type 2 diabetes. Hyperglycemia is associated with chronic low-grade inflammation, and thus has become the focus of many screening and treatment recommendations. We hypothesize that insulin may also be associated with inflammation and may be an additional factor to consider in screening and treatment. METHODS: This study used National Health and Nutrition Examination Survey data from 2005 to 2010 to analyze the association between fasting insulin and C-reactive protein (CRP). A two-part model was used due to the high number of values reported as 0.1 mg/L. Two models were analyzed, both with and without the addition of waist circumference to other covariates in the model. RESULTS: The final sample included 4527 adults with a mean age of 43.31 years. In the first model, higher fasting insulin was associated with increased odds of CRP > 0.1 mg/L (OR = 1.02, p < .001) and with higher CRP (β = 0.03, p < .001). In the adjusted model, including waist circumference as a covariate, higher fasting insulin was not associated with CRP > 0.1 mg/L (OR = 1.00, p = .307) but the association between higher fasting insulin and higher continuous CRP remained significant (β = 0.01, p = .012). CONCLUSION: This study found that higher fasting insulin is associated with higher CRP. These results suggest that treatment approaches that simultaneously decrease insulin levels as well as glucose levels may provide additive anti-inflammatory effects, and therefore may improve long-term outcomes for adults with type 2 diabetes.
Authors: Alan J Garber; Yehuda Handelsman; George Grunberger; Daniel Einhorn; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Michael A Bush; Ralph A DeFronzo; Jeffrey R Garber; W Timothy Garvey; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Leigh Perreault; Paul D Rosenblit; Susan Samson; Guillermo E Umpierrez Journal: Endocr Pract Date: 2020-01 Impact factor: 3.443
Authors: Yuan-Xiang Meng; Earl S Ford; Chaoyang Li; Alexander Quarshie; Ahmad M Al-Mahmoud; Wayne Giles; Gary H Gibbons; Gregory Strayhorn Journal: Clin Chem Date: 2007-10-19 Impact factor: 8.327
Authors: Aruna D Pradhan; Nancy R Cook; Julie E Buring; JoAnn E Manson; Paul M Ridker Journal: Arterioscler Thromb Vasc Biol Date: 2003-03-06 Impact factor: 8.311
Authors: Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian Journal: J Am Coll Cardiol Date: 2019-03-17 Impact factor: 24.094